Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance (Q40751928)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 May 2016

Language	Label	Description	Also known as
English	Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance	scientific article published on 17 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

0 references

Boris Hadaschik

object named as

B A Hadaschik

14

0 references

author name string

J P Radtke

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

T H Kuru

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

D Bonekamp

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

M T Freitag

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

M B Wolf

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

C D Alt

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

G Hatiboglu

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

S Boxler

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

S Pahernik

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

W Roth

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

M C Roethke

11

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

H P Schlemmer

12

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

M Hohenfellner

13

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

283-291

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

The contemporary concept of significant versus insignificant prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Identification of pathologically insignificant prostate cancer is not accurate in unscreened men.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Prostate Cancer: Multiparametric MRI for Index Lesion Localization—A Multiple-Reader Study

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Prospective validation of active surveillance in prostate cancer: the PRIAS study

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

ESUR prostate MR guidelines 2012

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Equivalence test and confidence interval for the difference in proportions for the paired-sample design

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

The role of biopsy core number in selecting prostate cancer patients for active surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance--How Many Cores are Enough?

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Can we expand active surveillance criteria to include biopsy Gleason 3 4 prostate cancer? A multi-institutional study of 2,323 patients

1 reference

https://api.crossref.org/works/10.1038/PCAN.2016.16

31 March 2020

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27184812

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/27184812

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/PCAN.2016.16

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40751928&oldid=2203949964"